Here is everything you need to know about retatrutide: what it is, how it works, what the trial data actually shows, and how it compares to the medications already on the market
Ending coverage for GLP-1 obesity drugs would be in line with current financial trends in both public and private insurance companies but could result in health inequities and less comprehensive coverage for a large segment of Rhode Islands population, the budget note reads
Keep your prescription documentation handy in case security has questions about syringes and vials
As the SELECT trial nears completion, a similar large trial was launched in autumn 2022, but this one involves a new wrinkle on GLP-1 receptor agonism that appears to yield even greater weight loss
Yield loss increases as peptides grow longer
Others prefer morning injections to align with their appetite suppression throughout the day